"Vaccines"[MAJR] AND clinical trial [pt] - Search Results

Year	Number of Results
1964	1
1965	11
1966	30
1967	33
1968	30
1969	60
1970	32
1971	27
1972	33
1973	37
1974	39
1975	51
1976	83
1977	96
1978	68
1979	69
1980	67
1981	82
1982	107
1983	90
1984	95
1985	88
1986	114
1987	128
1988	139
1989	114
1990	168
1991	183
1992	201
1993	187
1994	238
1995	259
1996	252
1997	310
1998	268
1999	357
2000	335
2001	294
2002	285
2003	336
2004	378
2005	422
2006	458
2007	540
2008	492
2009	500
2010	557
2011	686
2012	656
2013	634
2014	656
2015	684
2016	564
2017	541
2018	455
2019	461
2020	215
2021	22

1

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team. Vesikari T, et al. N Engl J Med. 2006 Jan 5;354(1):23-33. doi: 10.1056/NEJMoa052664. N Engl J Med. 2006. PMID: 16394299 Free article. Clinical Trial.

2

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, Dallas M, Hartzel J, Marchese RD, Coller BG, Stek JE, Abeygunawardana C, Winters MA, MacNair JE, Pujar NS, Musey L. Greenberg D, et al. Vaccine. 2018 Oct 29;36(45):6883-6891. doi: 10.1016/j.vaccine.2018.02.113. Epub 2018 Sep 21. Vaccine. 2018. PMID: 30244873 Clinical Trial.

3

A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.

Pan SC, Hsieh SM, Lin CF, Hsu YS, Chang M, Chang SC. Pan SC, et al. Vaccine. 2019 Mar 28;37(14):1994-2003. doi: 10.1016/j.vaccine.2019.02.006. Epub 2019 Mar 2. Vaccine. 2019. PMID: 30837170 Clinical Trial.

4

The Immunogenicity and Safety of a Combined DTaP-IPV//Hib Vaccine Compared with Individual DTaP-IPV and Hib (PRP~T) Vaccines: a Randomized Clinical Trial in South Korean Infants.

Kang JH, Lee HJ, Kim KH, Oh SH, Cha SH, Lee J, Kim NH, Eun BW, Kim CH, Hong YJ, Kim HH, Lee KY, Kim YJ, Cho EY, Kim HS, Guitton F, Ortiz E. Kang JH, et al. J Korean Med Sci. 2016 Sep;31(9):1383-91. doi: 10.3346/jkms.2016.31.9.1383. J Korean Med Sci. 2016. PMID: 27510380 Free PMC article. Clinical Trial.

5

Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.

Noh JY, Jang YS, Lee SN, Choi MJ, Yoon JG, Yu DH, Song JY, Cheong HJ, Kim WJ. Noh JY, et al. Vaccine. 2019 Aug 23;37(36):5171-5176. doi: 10.1016/j.vaccine.2019.07.076. Epub 2019 Jul 31. Vaccine. 2019. PMID: 31377075 Clinical Trial.

6

One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.

Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, Wirahmadi A, Puspita M, Sari RM, Yang JS, Sil A, Sahastrabuddhe S, Bachtiar NS. Medise BE, et al. Int J Infect Dis. 2020 Apr;93:102-107. doi: 10.1016/j.ijid.2020.01.045. Epub 2020 Jan 28. Int J Infect Dis. 2020. PMID: 32004693 Free article. Clinical Trial.

7

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.

Sharma S, Singh VB, Kumar S, Prajapati V, Patel J, Vukkala R, Jangid SK, Sanmukhani J, Gupta G, Patel P, Mittal R, Glueck R. Sharma S, et al. Hum Vaccin Immunother. 2018 Jun 3;14(6):1362-1369. doi: 10.1080/21645515.2018.1441654. Epub 2018 Mar 21. Hum Vaccin Immunother. 2018. PMID: 29461913 Free PMC article. Clinical Trial.

8

Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.

Chu K, Hu J, Meng F, Li J, Luo L, Xu J, Yuan Z, Li Z, Chen W, Jiao L, Chang Y, Wang B, Hu Y. Chu K, et al. Hum Vaccin Immunother. 2016 Sep;12(9):2334-40. doi: 10.1080/21645515.2016.1175261. Epub 2016 May 9. Hum Vaccin Immunother. 2016. PMID: 27159397 Free PMC article. Clinical Trial.

9

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.

Frenck RW Jr, Baqar S, Alexander W, Dickey M, McNeal M, El-Khorazaty J, Baughman H, Hoeper A, Barnoy S, Suvarnapunya AE, Kaminski RW, Venkatesan MM. Frenck RW Jr, et al. Vaccine. 2018 Aug 6;36(32 Pt B):4880-4889. doi: 10.1016/j.vaccine.2018.06.063. Epub 2018 Jul 2. Vaccine. 2018. PMID: 30037478 Clinical Trial.

10

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.

Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. Vesikari T, et al. Pediatr Infect Dis J. 2017 Feb;36(2):209-215. doi: 10.1097/INF.0000000000001406. Pediatr Infect Dis J. 2017. PMID: 27846055 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results